Forsythoside a as a potential therapeutic agent for non-alcoholic fatty liver disease: from target identification to in vitro and in vivo validation DOI
Yifu Feng, Zhirui Li,

Junbin Qian

и другие.

Natural Product Research, Год журнала: 2025, Номер unknown, С. 1 - 10

Опубликована: Апрель 26, 2025

Non-alcoholic fatty liver disease (NAFLD) is a long-term metabolic condition marked by unusual fat buildup in the liver, with an increasing occurrence worldwide. Forsythoside A (FA), bioactive component of Forsythia suspensa, has anti-inflammatory, antioxidative, and hepatoprotective effects. This study investigates mechanisms which FA may treat NAFLD. Using bioinformatics tools, 35 potential targets were identified, protein-protein interaction network was constructed. KEGG GO enrichment analyses highlighted important pathways associated The effects confirmed using both vitro vivo NAFLD models. Matrix Metalloproteinase 9 (MMP9), Tumour Necrosis Factor Alpha (TNFɑ), identified as core targets. analysis showed that affects metabolic, TNF signalling, insulin resistance pathways. In vivo, reduced lipid accumulation modulated TNFɑ, MMP9, ALB expression. modulating TNFɑ/MMP9/ALB pathway, providing new therapeutic insights for treatment.

Язык: Английский

Molecular structure and role of microbial proteins: a delimitation employing bioinformatics techniques DOI
Debanjan Saha,

Nayan Jyoti Borah,

Afrin Mamud

и другие.

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 273 - 300

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Subtractive genomics and drug repurposing strategies for targeting Streptococcus pneumoniae: insights from molecular docking and dynamics simulations DOI Creative Commons

Borakha Bura Gohain,

Bhaskar Mazumder, Sanchaita Rajkhowa

и другие.

Frontiers in Microbiology, Год журнала: 2025, Номер 16

Опубликована: Март 18, 2025

Streptococcus pneumoniae is a Gram-positive bacterium responsible for severe infections such as meningitis and pneumonia. The increasing prevalence of antibiotic resistance necessitates the identification new therapeutic targets. This study aimed to discover potential drug targets against S. using an in silico subtractive genomics approach. genome was compared human identify non-homologous sequences CD-HIT BLASTp. Essential genes were identified Database Genes (DEG), with consideration gut microflora. Protein-protein interaction analyses conducted key hub genes, gene ontology (GO) studies performed explore associated pathways. Due lack crystal structure data, target modeled subjected structure-based virtual screening. Approximately 2,000 2,027 proteins from humans. DEG 48 essential which reduced 21 after considering Key included gpi, fba, rpoD, trpS, 20 Virtual screening 2,509 FDA-approved compounds Bromfenac leading candidate, exhibiting binding energy -26.335 ± 29.105 kJ/mol. Bromfenac, particularly when conjugated AuAgCu2O nanoparticles, has demonstrated antibacterial anti-inflammatory properties Staphylococcus aureus. suggests that could be repurposed agent pneumoniae, pending further experimental validation. approach highlights repurposing by targeting pathogens but absent host.

Язык: Английский

Процитировано

0
Effects of Bare and PEG Coated Gold Nanoparticles on RRM2 Protein: A Pathway Analysis and MD Simulations Approach DOI
Ajit Kumar Singh, Anupam Nath Jha

BioNanoScience, Год журнала: 2025, Номер 15(2)

Опубликована: Апрель 8, 2025

Язык: Английский

Процитировано

0
Forsythoside a as a potential therapeutic agent for non-alcoholic fatty liver disease: from target identification to in vitro and in vivo validation DOI
Yifu Feng, Zhirui Li,

Junbin Qian

и другие.

Natural Product Research, Год журнала: 2025, Номер unknown, С. 1 - 10

Опубликована: Апрель 26, 2025

Non-alcoholic fatty liver disease (NAFLD) is a long-term metabolic condition marked by unusual fat buildup in the liver, with an increasing occurrence worldwide. Forsythoside A (FA), bioactive component of Forsythia suspensa, has anti-inflammatory, antioxidative, and hepatoprotective effects. This study investigates mechanisms which FA may treat NAFLD. Using bioinformatics tools, 35 potential targets were identified, protein-protein interaction network was constructed. KEGG GO enrichment analyses highlighted important pathways associated The effects confirmed using both vitro vivo NAFLD models. Matrix Metalloproteinase 9 (MMP9), Tumour Necrosis Factor Alpha (TNFɑ), identified as core targets. analysis showed that affects metabolic, TNF signalling, insulin resistance pathways. In vivo, reduced lipid accumulation modulated TNFɑ, MMP9, ALB expression. modulating TNFɑ/MMP9/ALB pathway, providing new therapeutic insights for treatment.

Язык: Английский

Процитировано

0